Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year Results.

Aristides K ManiatisSamuel J CasellaUlhas M NadgirPaul L HofmanPaul SaengerElena D ChertockElena M AghajanovaMaria Korpal-SzczyrskaElpis VlachopapadopoulouOleg MalievskiyTetyana ChaychenkoMarco CappaWenjie SongMeng MaoPer Holse MygindAlden R SmithSteven D ChesslerAllison S KomirenkoMichael BeckertAimee D ShuPaul S Thornton

Published in: The Journal of clinical endocrinology and metabolism (2022)

Treatment with lonapegsomatropin continued to be safe and well-tolerated, with no new safety signals identified. Children treated with once-weekly lonapegsomatropin showed continued improvement of height SDS through the second year of therapy without excess advancement of bone age.

Keyphrases

growth hormone
young adults
clinical trial
body mass index
study protocol
bone mineral density
randomized controlled trial
stem cells
phase iii
replacement therapy
phase ii
soft tissue
physical activity
open label
postmenopausal women
combination therapy
bone marrow